Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA‐1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.

Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know / Diotallevi, F; Campanati, A; Radi, G; Martina, E; Rizzetto, G; Barbadoro, P; D’Errico, Mm; Offidani, A. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - ELETTRONICO. - 35:7(2021), pp. 428-430. [10.1111/jdv.17256]

Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know

Diotallevi F;Campanati A;Martina E
;
Rizzetto G;Barbadoro P;D’Errico MM;
2021-01-01

Abstract

Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA‐1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.
File in questo prodotto:
File Dimensione Formato  
Diotallevi_Vaccination-against-SARS‐CoV‐2-psoriasis-three-things_2021.pdf

Solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso: Tutti i diritti riservati
Dimensione 367.38 kB
Formato Adobe PDF
367.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/300948
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact